Michael Shen, PhD, the Arthur J. Antenucci Professor of Medical Sciences and  professor of genetics, urology, and systems biology at Columbia’s Vagelos College of Physicians and Surgeons, has been named a fellow of the American Association for the Advancement of Science (AAAS)(link is external and opens in a new window). Dr. Shen, who also co-leads the Tumor Biology and Microenvironment research program at the Herbert Irving Comprehensive Cancer Center (HICCC), joins four other Columbia faculty members who have been elected to the 2021 class of AAAS fellows.

Read full article on Herbert Irving Comprehensive Cancer Center News Page

Chaolin Zhang, PhD, Associate Professor in Systems Biology will receive $2,766,392 over five years from the National Insititue of Neurological Disorders and Stroke for “RNA regulatory networks in neuronal cell type diversity and function”. This award will support Dr. Zhang to understand better post-transcriptional gene expression regulation through specific protein -RNA interactions, or RNA-regulatory networks which is critical for expanding the complexity of the mammalian nervous system with implications in an expanding list of neuronal disorders. The proposed studies will investigate alternative splicing regulation in generating the distinct molecular programs in diverse neuronal cell types of mouse cortex. Information obtained in this project will provide insights into the fundamental mechanisms that controls such diversity as well as the functional consequences in defined, clinically relevant neuronal cell types.

Honoring outstanding postdoctoral scientists from academic research institutions across New York, New Jersey, and Connecticut, the Blavatnik Family Foundation and the New York Academy of Sciences announced the three Winners and six Finalists of the 2021 Blavatnik Regional Awards for Young Scientists. 

Biologists aspire to understand every gene’s contribution to an organism’s biology and behavior. Microbiologist Wenyan Jiang has helped repurpose the CRISPR-Cas system, an immune system of many bacteria, and co-opt it to upgrade the way many scientists control and examine the genome. Jiang developed a groundbreaking tool called CRISPR Adaptation-mediated Library Manufacturing (CALM), which exploits CRISPR RNA, a type of RNA naturally found in bacteria. CALM has enabled scientists to quickly determine the causal link between genes and bacterial behaviors such as antibiotic resistance and pathogenesis and pave the way for developing new, effective antimicrobial drugs. 

Read full article on Blavatnik Award site

The annual Precision Medicine Pilot Grants have been awarded to five teams of  researchers conducting innovative basic science, translational, and clinical research across multiple diseases. 

Jointly awarded by the Columbia Precision Medicine Initiative (CPMI), the Herbert Irving Comprehensive Cancer Center (HICCC), and the Irving Institute for Clinical and Translational Research (Irving Institute), the Precision Medicine Pilot Grants underscore Columbia’s commitment to supporting diverse, cross-disciplinary research targeting the promise of precision medicine.

The five winning teams are being led by faculty at Columbia’s Vagelos College of Physicians & Surgeons (VP&S), including: Srilaxmi Bearelly, MD, associate  professor of ophthalmology; Brian Henick, MD, assistant professor of medicine; Chi-Min Ho, PhD, assistant professor of microbiology and immunology; Yufeng Shen, PhD, associate professor of systems biology and of biomedical informatics; and Xuebing Wu, PhD, assistant professor of systems biology and of medicine. The projects being funded are focusing on a range of research, from novel cancer therapeutics to health disparities research. 

The Vagelos Precision Medicine Pilot Grant program is made possible by a generous donation from Roy and Diana Vagelos and is intended to support groundbreaking basic research in the field of precision medicine. Each research team receives $100,000 in funding for one year. The researchers will present their projects at an annual symposium for the precision medicine awards in fall 2022.

Read full article in the HICCC Newsroom

Melissa McKenzie, PhD, a second-year postdoctoral research scientist in the lab of Chaolin Zhang , PhD, has been awarded a K99/R00 “Pathway to Independence” award. This honor supports her goal to identify how alternative RNA splicing networks influence cortical interneuron specification.

Dr. McKenzie graduated summa cum laude from Cornell University where she was an Irving Tanner Dean’s scholar double majoring in biological sciences and philosophy. She joined the Zhang lab with a growing interest in leveraging emerging sequencing and other genomics technologies to investigate the role of RNA transcripts in the developing brain. 

This award program is designed to facilitate a timely transition of outstanding postdoctoral researchers or clinician-scientists from mentored research positions to independent, tenure-track or equivalent faculty positions, and to provide independent NIH research support during the transition that will help these individuals launch competitive, independent research careers.

Read more about Dr. McKenzie and research by the Zhang lab . 

Tal Korem, PhD, Systems Biology and Obstetrics & Gynecology, will receive $307,136 over five years from the National Institute of Nursing Research for a subaward of “The Role of Host-Microbial Interactions in Altering Preterm Birth Risk Among Black Women.”

Read the full article in the CUIMC Newsroom.

Sagi Shapira,PhD, assistant professor of systems biology at Columbia’s Vagelos College of Physicians & Surgeons and Nicholas Tatonetti, PhD, associate professor of bioinformatics and of systems biology at VP&S, have recently been awarded a new pilot grant to support their collaboration in COVID-19 research.

Drs. Shapira and Tatonetti are one of three teams who have been awarded a COVID-19 research pilot grant from the Herbert Irving Comprehensive Cancer Center. The pair will work on accurately identifying pathophysiological factors that modulate SARS-CoV-2 infection and explain variability in disease outcomes.

Read the full article here. 

Dr. Harris Wang is lead PI on a new DARPA-funded project developing novel therapies to counter effects of high-dose ionizing radiation.

Harris Wang, PhD, assistant professor of systems biology at Columbia University Irving Medical Center , is leading a team of experts in radiation research, CRISPR-Cas technologies, and drug delivery on an innovative new project announced June 27 funded by the Defense Advanced Research Projects Agency (DARPA) . The up to $9.5M project focuses on pursuing a therapy to protect the body from the effects of high-dose ionizing radiation, and is part of DARPA's initiative to fund research into new strategies to combat public health and national security threats.

In humans, acute radiation syndrome primarily affects stem cells in the blood and gut, yet existing treatments only help to regenerate blood cells, and only with limited effect. There is no possibility for prophylactic administration of these drugs, and most must be delivered immediately following radiation exposure to provide any benefit. There are no existing medical countermeasures for radiation damage to the gut.

The Columbia team aims to develop an orally delivered programmable gene modulator therapeutic. The multimodal treatment the team envisions would take hold in both the gut and liver, triggering protection and regeneration of intestinal cells, while also inducing liver cells to produce protective cues that trigger the regeneration of blood cells in bone marrow.